These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20638574)

  • 21. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of bias in MoM values on patient risk and screening performance for Down syndrome.
    Nix B; Wright D; Baker A
    Prenat Diagn; 2007 Sep; 27(9):840-5. PubMed ID: 17600858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which contingent sequential screening protocol?
    Larsen SO; Christiansen M; Norgaard-Pedersen B
    Prenat Diagn; 2005 Dec; 25(12):1168-9; author reply 1169-70. PubMed ID: 16317663
    [No Abstract]   [Full Text] [Related]  

  • 24. Second-trimester prenatal screening for trisomy 21 using biochemical markers: a 7-year experience in one cytogenetic laboratory.
    Marical H; Douet-Guilbert N; Bages K; Collet M; Le Bris MJ; Morel F; De Braekeleer M
    Prenat Diagn; 2006 Apr; 26(4):308-12. PubMed ID: 16491510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuchal translucency and first-trimester screening.
    Harry WG; Reed KL
    J Soc Gynecol Investig; 2006 Apr; 13(3):153-4. PubMed ID: 16638584
    [No Abstract]   [Full Text] [Related]  

  • 26. First-trimester Down syndrome screening performance in the Dutch population; how to achieve further improvement?
    Wortelboer EJ; Koster MP; Stoutenbeek P; Elvers LH; Loeber JG; Visser GH; Schielen PC
    Prenat Diagn; 2009 Jun; 29(6):588-92. PubMed ID: 19294632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First- and second-trimester Down syndrome screening: current strategies and clinical guidelines.
    Shaw SW; Hsu JJ; Lee CN; Hsiao CH; Chen CP; Hsieh TT; Cheng PJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):157-62. PubMed ID: 18603499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expectation and knowledge of women undergoing first-trimester combined screening for Down syndrome in a Chinese population.
    Chan LW; Chau MC; Leung TY; Fung TY; Leung TN; Lau TK
    Prenat Diagn; 2005 Dec; 25(13):1248-52. PubMed ID: 16353273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-stage contingent screening for Down syndrome.
    Wright D; Bradbury I; Cuckle H; Gardosi J; Tonks A; Standing S; Benn P
    Prenat Diagn; 2006 Jun; 26(6):528-34. PubMed ID: 16634118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A summary analysis of Down syndrome markers in the late first trimester.
    Palomaki GE; Lambert-Messerlian GM; Canick JA
    Adv Clin Chem; 2007; 43():177-210. PubMed ID: 17249384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation.
    Bahado-Singh RO; Oz AU; Gomez K; Hunter D; Copel J; Baumgarten A; Mahoney MJ
    Ultrasound Obstet Gynecol; 2000 Mar; 15(3):199-204. PubMed ID: 10846774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contingent screening for Down syndrome--results from the FaSTER trial.
    Cuckle HS; Malone FD; Wright D; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Ferreira JC; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; D'Alton ME
    Prenat Diagn; 2008 Feb; 28(2):89-94. PubMed ID: 18236423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuchal translucency-based Down syndrome screening: barriers to implementation.
    Malone FD
    Semin Perinatol; 2005 Aug; 29(4):272-6. PubMed ID: 16104681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance adjusted risks: a method to improve the quality of algorithm performance while allowing all to play.
    Evans MI; Cuckle HS
    Prenat Diagn; 2011 Aug; 31(8):797-801. PubMed ID: 21692089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintaining quality assurance for sonographic nuchal translucency measurement: lessons from the FASTER Trial.
    D'Alton ME; Cleary-Goldman J; Lambert-Messerlian G; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor IE; Carr SR; Wolfe HM; Dukes K; Canick JA; Malone FD
    Ultrasound Obstet Gynecol; 2009 Feb; 33(2):142-6. PubMed ID: 19173241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semi-automated measurement of nuchal translucency thickness: blasphemy or oblation to quality?
    Ville Y
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):400-3. PubMed ID: 20872935
    [No Abstract]   [Full Text] [Related]  

  • 39. Screening in the presence of a vanished twin: nuchal translucency or combined screening test?
    Sankaran S; Rozette C; Dean J; Kyle P; Spencer K
    Prenat Diagn; 2011 Jun; 31(6):600-1. PubMed ID: 21413040
    [No Abstract]   [Full Text] [Related]  

  • 40. Second-trimester sonographic soft markers: what can we learn from the experience of first-trimester nuchal translucency screening?
    Lau TK; Evans MI
    Ultrasound Obstet Gynecol; 2008 Aug; 32(2):123-5. PubMed ID: 18663770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.